Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Rapid Therapeutic Science Laboratories, Inc. (RTSL) Cash from Operations (2016 - 2023)

Rapid Therapeutic Science Laboratories' Cash from Operations history spans 8 years, with the latest figure at 7325.0 for Q2 2023.

  • For Q2 2023, Cash from Operations fell 111.24% year-over-year to 7325.0; the TTM value through Jun 2023 reached 566601.0, up 70.13%, while the annual FY2022 figure was 1151709.0, 47.87% up from the prior year.
  • Cash from Operations for Q2 2023 was 7325.0 at Rapid Therapeutic Science Laboratories, up from 41814.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 65175.0 in Q2 2022 and bottomed at 1138098.0 in Q3 2020.
  • The 5-year median for Cash from Operations is 190252.5 (2020), against an average of 310493.44.
  • The largest annual shift saw Cash from Operations tumbled 3031.8% in 2020 before it skyrocketed 115.44% in 2022.
  • A 5-year view of Cash from Operations shows it stood at 32977.0 in 2019, then tumbled by 3351.19% to 1138098.0 in 2020, then surged by 51.51% to 551864.0 in 2021, then surged by 36.21% to 352049.0 in 2022, then surged by 97.92% to 7325.0 in 2023.
  • Per Business Quant, the three most recent readings for RTSL's Cash from Operations are 7325.0 (Q2 2023), 41814.0 (Q1 2023), and 352049.0 (Q4 2022).